Chinese biotechnology firm MGI Tech has partnered with Brazilian diagnostic labs chain Sabin Group to boost personalised medicine in Brazil through oncological and germiline genomics.
The partnership will focus on enhancing health detection through advanced genetic sequencing technology.
It aims to expand Sabin’s exam portfolio and increase access to new genomics tests for Brazilians.
Sabin Group has been operating in 15 Brazilian states for four decades. The group serves over seven million customers annually, offering a wide range of clinical analysis, diagnostic imaging, vaccination, and examination services.
The partnership between MGI Tech and Sabin will help advance personalised medicine in Brazil.
By expanding access to advanced genetic sequencing, the collaboration enables more accurate diagnoses and personalised treatments based on each patient’s genetic profile.
According to MGI Tech, this improves clinical outcomes and promotes a more preventive and efficient healthcare approach, transforming medical practice in the country.
MGI Latin America senior commercial director and Brazil general manager Carlos Carpio said: “The combination of our cutting-edge technology with Sabin’s vast network and expertise will create a unique synergy that can transform the Brazilian healthcare system.
“Sabin has a strong and consolidated presence in the country and by incorporating our genetic sequencing solutions, we can offer more accurate and accessible diagnostics to a broad patient base.
“This partnership has the potential to raise the standard of care and promote more personalised and efficient medicine in the country.”
By identifying genetic predispositions and enabling accurate diagnoses, patients can receive more effective, personalised treatments. This will positively impact public health and help reduce healthcare system costs, the Chinese biotechnology firm said.
Sabin has implemented the DNBSEQ-G400 genomic sequencer, enabling large- and medium-scale sequencing, along with the MGISP-100, an automated library preparation system for DNA sequencing.
Since adopting the DNBSEQ-G400, Sabin has seen a 78% increase in genomic tests, boosting its capacity to deliver advanced diagnostics, MGI Tech added.
The MGISP-100 automates sample processing, eliminating repetitive tasks, enhancing library preparation stability, reducing costs, and improving laboratory efficiency.
These advancements are expected to accelerate growth, further advancing personalised medicine in Brazil.
In April this year, MGI opened the Customer Experience Center (CEC) in Brazil to enhance genomic sequencing infrastructure and support scientific development in the country.
Earlier this month, the genome sequencing machine provider partnered with the Universidad de San Martín de Porres to boost human genetics research.
